Administration methods and dosage of poly(lactic acid)-glycol intervention to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalitis mice

BACKGROUND: Myelin oligodendrocyte glycoprotein-associated disorders (MOGAD) is an autoimmune central nervous system disease.

Antigen-specific immune tolerance using nanoparticles such as Polylactic-co-glycolic acid (PLGA) have recently been used as a new therapeutic tolerization approach for CNS autoimmune diseases.

We examined whether MOG(1-125) conjugated with PLGA could induce MOG-specific immune tolerance in an experimental autoimmune encephalitis (EAE) mouse model.

EAE was induced in sixty C57BL/6 J wild-type mice using MOG(1-125) peptide with complete Freund’s Adjuvant.

The mice were divided into 12 groups (n = 5 each) to test the ability of MOG(1-125) conjugated PLGA intervention to mitigate the severity or improve the outcomes from EAE with and without rapamycin compared to antigen alone or PLGA alone.

EAE score and serum MOG-IgG titers were compared among the interventions.Kindly check and confirm the processed Affiliation “4” is appropriate.I confirmed the Aff 4.

Affiliation: Corresponding author information have been changed to present affiliation.

Kindly check and confirm.I checked and confirmed the Corresponding author's information.

RESULTS: Mice with EAE that were injected intraperitoneally with MOG(1-125) conjugated PLGA + rapamycin complex showed dose-dependent mitigation of EAE score.

Intraperitoneal and intravenous administration resulted in similar clinical outcomes, whereas 80% of mice treated with subcutaneous injection had a recurrence of clinical score worsening after approximately 1 week.

Although there was no significant difference in EAE scores between unconjugated-PLGA and MOG-conjugated PLGA, serum MOG-IgG tended to decrease in the MOG-conjugated PLGA group compared to controls.

CONCLUSION: Intraperitoneal administration of PLGA resulted in dose-dependent and longer-lasting immune tolerance than subcutaneous administration.

The induction of immune tolerance using PLGA may represent a future therapeutic option for patients with MOGAD.